# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN
- Date: 2026-09-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Simon Achterberg, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Diagnosis and staging review. **S**

## History of present illness

Mr. Brynner returns two weeks after his first visit. His PET-CT and brain MRI were done eleven days ago, and the endobronchial ultrasound biopsy six days ago. He saw the thoracic oncologist this morning and was told he has adenocarcinoma of the lung that has spread to three bones. His voice is still weak and breathy, and he has not sung since the tour paused. He has a little dry cough in the mornings, no blood in his sputum, and no breathlessness on the level. He has no bone, back, rib, or hip pain, no headache, and no weakness or numbness. His weight is steady. He is sleeping less well with worry, but he says he wants every fact and wants to get back on stage. He has not smoked for 12 years. **S**

| Element | Detail |
|---|---|
| Results since last visit | PET-CT and brain MRI; endobronchial ultrasound biopsy: adenocarcinoma, PD-L1 70 percent; plasma testing without an actionable alteration; tissue sequencing pending |
| Voice | Weak and breathy; not singing |
| Respiratory | Morning dry cough; no hemoptysis; no breathlessness on the level |
| Bone and neurological symptoms | None |
| Coping | Worried and sleeping less; distress thermometer 6 of 10 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Morning dry cough; breathless on two flights of stairs; no hemoptysis |
| Musculoskeletal | Negative | No bone, back, rib, or hip pain |
| Neurological | Negative | No headache, weakness, numbness, or unsteadiness |
| Psychiatric | Positive | Worried; sleeping about five hours; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 96% on room air; weight 72 kg; BMI 22.7 kg/m². All vital signs are synthetic.

ESAS total symptom distress score: 18. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Upright and composed; weight 72.0 kg |
| Voice | Breathy, low-volume voice; short phonation time |
| Lungs | Slightly reduced breath sounds at the left apex; no wheeze or crackles |
| Lymph nodes | No supraclavicular or cervical nodes |
| Spine and pelvis | No tenderness over T10, the ribs, or the right iliac crest |
| Neurological | Normal strength, sensation, and gait |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adenocarcinoma of the left upper lobe, stage IVB (cT4 N2 M1c)** (C34.12). Tissue diagnosis made: adenocarcinoma, TTF-1 positive, PD-L1 tumor proportion score 70 percent. Staged by PET-CT and brain MRI: mediastinal invasion (T4), aortopulmonary window and subcarinal nodes (N2), and three bone metastases (M1c); no brain metastases. ECOG 1. Plasma testing shows no actionable alteration; tissue sequencing is still pending. The thoracic oncologist recommends first-line pembrolizumab if tissue sequencing confirms no actionable alteration, and not starting an immune checkpoint inhibitor before that result. **S**
   - Await tissue sequencing, expected within a week; treatment decision at the next visit.
   - Baseline immune-related adverse event laboratory panel before the first infusion.
   - Dental examination on Friday, before a bone-modifying agent.
   - Palliative care visit in two weeks.
2. **Bone metastases, without pain or fracture** (C79.51). Three lytic lesions without pain, fracture, or threatened cord; calcium normal. **S**
   - Zoledronic acid every 12 weeks after the dental examination.
   - Call at once for new back pain, leg weakness, or numbness.
3. **Left vocal fold paralysis** (J38.01). Hoarseness from recurrent laryngeal nerve involvement; recovery is unlikely while the tumor is present, but injection medialization can restore much of his voice. **S**
   - Injection medialization by the ENT surgeon in three weeks.
   - Voice therapy with a speech-language pathologist.
4. **Former smoker** (Z87.891). No tobacco for 12 years; no cessation treatment needed. **S**
   - Confirm abstinence at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PD-L1 immunohistochemistry (tumor proportion score) | At diagnosis; repeat at progression | Completed today | 22C3 assay on the endobronchial ultrasound sample: tumor proportion score 70 percent |
| Laboratory | Broad molecular profiling (tissue and plasma) | At diagnosis of advanced nonsquamous NSCLC: EGFR, ALK, ROS1, BRAF, KRAS (including G12C), MET exon 14, RET, NTRK, HER2, NRG1, and PD-L1; repeat at progression | Ordered | Plasma cell-free DNA: no actionable alteration. Tissue next-generation sequencing pending; therapy waits for it |
| Imaging | Staging PET-CT and brain MRI | At diagnosis of suspected advanced disease | Completed today | Reviewed today: cT4 N2 M1c (bone), no brain metastases |
| Laboratory | Immune-related adverse event laboratory panel | Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated | Due | Baseline panel before the first infusion |
| Imaging | Response assessment imaging | Every 6 to 12 weeks on active systemic therapy | Not indicated | No systemic therapy started yet |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Morning dry cough; breathless on two flights of stairs; no hemoptysis |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco for 12 years |
| Survey | Distress and symptom screening (NCCN Distress Thermometer, ESAS) | Every visit; at minimum at key transitions | Completed today | Distress thermometer 6 of 10 (worry, work, voice); ESAS total 18 |
| Survey | Cancer-related fatigue screening | Every visit | Completed today | Tires by evening; ESAS tiredness 4 of 10 |
| Survey | Depression and anxiety screening | At least yearly; more often during active treatment | Up to date | PHQ-9 5 two weeks ago; rescreen during treatment |
| Examination | Weight and dietary review | Each follow-up | Completed today | 72.0 kg, stable; eating normally |
| Medication safety | Dental evaluation before a bone-modifying agent | Baseline, then periodically on zoledronic acid or denosumab | Due | Dental examination booked for Friday |
| Medication safety | Chemotherapy-induced peripheral neuropathy | Every visit during and after platinum or taxane | Not indicated | No platinum or taxane planned |
| Referral | Thoracic oncology consultation | At diagnosis | Completed today | Seen today; stage IVB confirmed; pembrolizumab planned if tissue sequencing shows no actionable alteration |
| Referral | Early integrated palliative care | Within eight weeks of diagnosis of advanced cancer | Referred | First visit in two weeks |
| Self-management | Advance care planning and goals of care | At diagnosis and at changes in health | Completed today | First conversation today: he wants full information and full treatment, and to return to the stage |
| Self-management | Voice and work support | As needed | Referred | Injection medialization and voice therapy arranged |
| Medication safety | Immunizations per ACIP | Yearly review | Due | Influenza, pneumococcal, zoster, COVID-19, and RSV to be reviewed at the preventive visit |
| Examination | Pulmonary rehabilitation | Before and after lung resection, or for symptomatic dyspnea or deconditioning | Not indicated | No resection; not deconditioned |

## Goal progress

- Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation. In progress; target 2026-09-22. **S**
- First palliative care visit within eight weeks of diagnosis. In progress; target 2026-10-13. **S**
- A voice strong enough for rehearsal by the second cycle. In progress; target 2026-10-13. **S**
- No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit. In progress; target 2026-10-13. **S**
- Zoledronic acid started only after a dental examination and normal calcium and kidney function. In progress; target 2026-10-13. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021), American Society of Clinical Oncology (Schneider BJ et al., J Clin Oncol 2021;39(36):4073-4126)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Ferrell BR et al., J Clin Oncol 2017;35(1):96-112)
- NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026), National Comprehensive Cancer Network

## Follow-up

- Dental examination on Friday. Visit next week for the tissue sequencing result and the treatment start. Palliative care in two weeks. Voice injection in three weeks. **S**
- Next scheduled visit 2026-09-22: biomarker results and start of first-line pembrolizumab. **S**
